Loading...
VIMIAN logo

Vimian Group AB (publ)OM:VIMIAN Stock Report

Market Cap SEK 15.5b
Share Price
SEK 29.36
My Fair Value
n/a
1Y-31.6%
7D-3.4%
Portfolio Value
​
View

Vimian Group AB (publ)

OM:VIMIAN Stock Report

Market Cap: SEK 15.5b

Vimian Group (VIMIAN) Stock Overview

Engages in the animal health business worldwide. More details

VIMIAN fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance4/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 9.9% below our estimate of its fair value

Earnings are forecast to grow 40.38% per year

Earnings grew by 18539.1% over the past year

Analysts in good agreement that stock price will rise by 32.2%

Risk Analysis

VIMIAN passed our risk checks.

VIMIAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

VIMIAN logo
Vimian Group

Rising Interest Rates And Tariffs Will Weaken US MedTech Margins

Key Takeaways Reliance on acquisitions and exposure to rising rates and tariffs heighten operational risk and threaten predictable earnings and margin stability. Structural decline in key U.S. markets and digital disruption may erode market share, compress margins, and hinder long-term growth.
View narrative
SEK 37.32
FV
21.3% undervalued intrinsic discount
11.15%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
VIMIAN logo
Vimian Group

Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare

Key Takeaways MedTech and Specialty Pharma segments are poised for above-market organic growth and margin expansion through education, innovation, and accelerated product launches. Strategic acquisitions, rising global pet care demand, and digital healthcare investments bolster international diversification, margin gains, and long-term premium valuation potential.
View narrative
SEK 51.65
FV
43.2% undervalued intrinsic discount
12.55%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
VIMIAN logo
Vimian Group

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

Key Takeaways Sustained demand for advanced veterinary care and expansion in niche, high-margin segments position Vimian for recurring revenue and profit growth. Strategic acquisitions, digital adoption, and operational improvements support increased market share, new growth avenues, and recovery in underperforming areas.
View narrative
SEK 38.9
FV
24.5% undervalued intrinsic discount
9.67%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
View Stock Community

Vimian Group AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vimian Group
Historical stock prices
Current Share PriceSEK 29.36
52 Week HighSEK 47.30
52 Week LowSEK 27.80
Beta1.51
1 Month Change5.08%
3 Month Change-7.67%
1 Year Change-31.64%
3 Year Change-16.07%
5 Year Changen/a
Change since IPO-63.71%

Recent News & Updates

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Recent updates

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Sep 10
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 40% Above Its Share Price

Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Aug 14
Vimian Group AB (publ) (STO:VIMIAN) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)

Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
User avatar

iM3 Acquisition Will Expand Presence In Veterinary Dental Space

Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

Dec 03
Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Nov 01
There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price

Aug 27
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price

When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?

Jul 19
When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?

Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?

May 19
Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Apr 04
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Jan 06
Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Dec 09
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Shareholder Returns

VIMIANSE Medical EquipmentSE Market
7D-3.4%-1.4%-2.3%
1Y-31.6%-13.6%0.5%

Return vs Industry: VIMIAN underperformed the Swedish Medical Equipment industry which returned -12.2% over the past year.

Return vs Market: VIMIAN underperformed the Swedish Market which returned 2.8% over the past year.

Price Volatility

Is VIMIAN's price volatile compared to industry and market?
VIMIAN volatility
VIMIAN Average Weekly Movement4.6%
Medical Equipment Industry Average Movement6.8%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.6%
10% least volatile stocks in SE Market2.9%

Stable Share Price: VIMIAN has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: VIMIAN's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20201,200Carl-Johan Boudrievimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

Vimian Group AB (publ) Fundamentals Summary

How do Vimian Group's earnings and revenue compare to its market cap?
VIMIAN fundamental statistics
Market capSEK 15.47b
Earnings (TTM)SEK 348.24m
Revenue (TTM)SEK 4.65b
44.4x
P/E Ratio
3.3x
P/S Ratio

Is VIMIAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIMIAN income statement (TTM)
Revenue€421.00m
Cost of Revenue€132.10m
Gross Profit€288.90m
Other Expenses€257.40m
Earnings€31.50m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

Feb 12, 2026

Earnings per share (EPS)0.06
Gross Margin68.62%
Net Profit Margin7.48%
Debt/Equity Ratio36.5%

How did VIMIAN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/06 05:13
End of Day Share Price 2025/11/06 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vimian Group AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Hassan Al-WakeelBarclays
Blanka PorkolabBarclays